Skip to main content

Advertisement

Figure 3 | Stem Cell Research & Therapy

Figure 3

From: Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies

Figure 3

Assessment of renal function in adipose-derived mesenchymal stem cell (aMSC)-treated cats. (A) Serum creatinine values for cats in pilot study 1, who received three doses of 2 × 106 cryopreserved aMSCs intravenously 2 weeks apart. A statistically significant decrease in creatinine is seen (P = 0.01), however the degree of decrease may not be clinically significant. (B) Serum creatinine values for cats in pilot study 2, who received three doses of 4 × 106 cryopreserved aMSCs intravenously 2 weeks apart. No significant difference in creatinine was detected. (C) Serum creatinine values for cats in pilot study 3, who received three doses of 4 × 106 aMSCs cultured from cryopreserved adipose intravenously 2 weeks apart. No significant difference in creatinine was detected. (D) Estimated glomerular filtration rate (GFR) by iohexol clearance results at 0 and 8 weeks for five cats in pilot study 2 that received 4 × 106 cryopreserved aMSCs intravenously every 2 weeks for three treatments. Control chronic kidney disease cats had GFR performed at 0 and 8 weeks only. (E) GFR determined by nuclear scintigraphy results at 0 and 8 weeks for five cats in pilot study 3 that received 4 × 106 aMSCs cultured from cryopreserved adipose intravenously every 2 weeks for three treatments.

Back to article page